Literature DB >> 31082431

Non-receptor tyrosine kinase signaling in autoimmunity and therapeutic implications.

Sabrina Solouki1, Avery August2, Weishan Huang3.   

Abstract

Autoimmune diseases are characterized by impaired immune tolerance towards self-antigens, leading to enhanced immunity to self by dysfunctional B cells and/or T cells. The activation of these cells is controlled by non-receptor tyrosine kinases (NRTKs), which are critical mediators of antigen receptor and cytokine receptor signaling pathways. NRTKs transduce, amplify and sustain activating signals that contribute to autoimmunity, and are counter-regulated by protein tyrosine phosphatases (PTPs). The function of and interaction between NRTKs and PTPs during the development of autoimmunity could be key points of therapeutic interference against autoimmune diseases. In this review, we summarize the current state of knowledge of the functions of NRTKs and PTPs involved in B cell receptor (BCR), T cell receptor (TCR), and cytokine receptor signaling pathways that contribute to autoimmunity, and discuss their targeting for therapeutic approaches against autoimmune diseases.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  Autoantibodies; Autoimmunity; Effector T cells; Kinase Inhibitors; Non-receptor tyrosine kinase; Protein Tyrosine Phosphatase

Mesh:

Substances:

Year:  2019        PMID: 31082431      PMCID: PMC6738557          DOI: 10.1016/j.pharmthera.2019.05.008

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  171 in total

1.  Enhanced Bruton's Tyrosine Kinase Activity in Peripheral Blood B Lymphocytes From Patients With Autoimmune Disease.

Authors:  Odilia B J Corneth; Gwenny M P Verstappen; Sandra M J Paulissen; Marjolein J W de Bruijn; Jasper Rip; Melanie Lukkes; Jan Piet van Hamburg; Erik Lubberts; Hendrika Bootsma; Frans G M Kroese; Rudi W Hendriks
Journal:  Arthritis Rheumatol       Date:  2017-05-10       Impact factor: 10.995

2.  Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor.

Authors:  Polly R Pine; Betty Chang; Nathan Schoettler; Mona L Banquerigo; Su Wang; Angela Lau; Feifei Zhao; Elliott B Grossbard; Donald G Payan; Ernest Brahn
Journal:  Clin Immunol       Date:  2007-05-29       Impact factor: 3.969

Review 3.  Mechanisms of regulatory T-cell suppression - a diverse arsenal for a moving target.

Authors:  Dorothy K Sojka; Yu-Hui Huang; Deborah J Fowell
Journal:  Immunology       Date:  2008-03-14       Impact factor: 7.397

Review 4.  Type 1 diabetes: etiology, immunology, and therapeutic strategies.

Authors:  Tom L van Belle; Ken T Coppieters; Matthias G von Herrath
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

5.  Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice.

Authors:  Laurens P Kil; Marjolein J W de Bruijn; Menno van Nimwegen; Odilia B J Corneth; Jan Piet van Hamburg; Gemma M Dingjan; Friedrich Thaiss; Guus F Rimmelzwaan; Dirk Elewaut; Dianne Delsing; Pieter Fokko van Loo; Rudi W Hendriks
Journal:  Blood       Date:  2012-03-01       Impact factor: 22.113

Review 6.  How regulatory T cells work.

Authors:  Dario A A Vignali; Lauren W Collison; Creg J Workman
Journal:  Nat Rev Immunol       Date:  2008-07       Impact factor: 53.106

7.  The K/BxN arthritis model.

Authors:  Paul A Monach; Diane Mathis; Christophe Benoist
Journal:  Curr Protoc Immunol       Date:  2008-05

Review 8.  Unravelling the association of partial T-cell immunodeficiency and immune dysregulation.

Authors:  Adrian Liston; Anselm Enders; Owen M Siggs
Journal:  Nat Rev Immunol       Date:  2008-07       Impact factor: 53.106

9.  B cell-specific loss of Lyn kinase leads to autoimmunity.

Authors:  Chrystelle Lamagna; Yongmei Hu; Anthony L DeFranco; Clifford A Lowell
Journal:  J Immunol       Date:  2013-12-27       Impact factor: 5.422

10.  Constitutive STAT3 Phosphorylation in Circulating CD4+ T Lymphocytes Associates with Disease Activity and Treatment Response in Recent-Onset Rheumatoid Arthritis.

Authors:  Krista Kuuliala; Antti Kuuliala; Riitta Koivuniemi; Suvi Oksanen; Mari Hämäläinen; Eeva Moilanen; Hannu Kautiainen; Marjatta Leirisalo-Repo; Heikki Repo
Journal:  PLoS One       Date:  2015-09-09       Impact factor: 3.240

View more
  5 in total

Review 1.  Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective.

Authors:  Yang Yang; Shuo Li; Yujiao Wang; Yi Zhao; Qiu Li
Journal:  Signal Transduct Target Ther       Date:  2022-09-17

Review 2.  COVID-19 and pulmonary fibrosis: therapeutics in clinical trials, repurposing, and potential development.

Authors:  Joowon Yim; Hee Hyun Lim; Youngjoo Kwon
Journal:  Arch Pharm Res       Date:  2021-05-28       Impact factor: 6.010

Review 3.  The Src-family Kinase Lyn in Immunoreceptor Signaling.

Authors:  Ben F Brian; Tanya S Freedman
Journal:  Endocrinology       Date:  2021-10-01       Impact factor: 5.051

Review 4.  BTK/ITK dual inhibitors: Modulating immunopathology and lymphopenia for COVID-19 therapy.

Authors:  Michael C McGee; Avery August; Weishan Huang
Journal:  J Leukoc Biol       Date:  2020-07-08       Impact factor: 6.011

5.  Immunopharmacology and Quantitative Analysis of Tyrosine Kinase Signaling.

Authors:  Ben F Brian; Candace R Guerrero; Tanya S Freedman
Journal:  Curr Protoc Immunol       Date:  2020-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.